Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

JSPR Jasper Therapeutics

Market Closed 05-15 16:00:00 EDT

0.8501

-0.1089

-11.36%

盘后0.8300

-0.0201-2.36%

19:57 EDT

High0.9299	Low0.8050	Vol661.76K
Open0.9161	D1 Closing0.9590	Amplitude13.02%
Mkt Cap23.79M	Tradable Cap19.39M	Total Shares27.98M
T/O552.39K	T/O Rate2.90%	Tradable Shares22.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"JSPR","market":"US","secType":"STK","nameCN":"Jasper Therapeutics","latestPrice":0.8501,"timestamp":1778875200000,"preClose":0.959,"halted":0,"volume":661756,"hourTrading":{"tag":"盘后","latestPrice":0.83,"preClose":0.8501,"latestTime":"19:57 EDT","volume":2209,"amount":1858.3264,"timestamp":1778889435690,"change":-0.0201,"changeRate":-0.023644,"amplitude":0.035408},"delay":0,"changeRate":-0.11355578727841502,"floatShares":22810300,"shares":27984039,"eps":-3.954536,"marketStatus":"Market Closed","change":-0.1089,"latestTime":"05-15 16:00:00 EDT","open":0.9161,"high":0.9299,"low":0.805,"amount":552393.6078596,"amplitude":0.13024,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.954536,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.959,"preHourTrading":{"tag":"盘前","latestPrice":0.9252,"preClose":0.959,"latestTime":"08:37 EDT","volume":1000,"amount":925.2,"timestamp":1778848665795,"change":-0.0338,"changeRate":-0.035245,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.83,"preClose":0.8501,"latestTime":"19:57 EDT","volume":2209,"amount":1858.3264,"timestamp":1778889435690,"change":-0.0201,"changeRate":-0.023644,"amplitude":0.035408},"volumeRatio":3.3821470143229746,"impliedVol":5.099,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/JSPR","defaultTab":"news","newsList":[{"id":"2635038400","title":"Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635038400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635038400?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:13","pubTimestamp":1778854380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 10:13 ET (14:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","BK4139","LU0708994859.HKD","LU0029864427.USD","JSPR","LU1267930573.SGD","LU0128525929.USD","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087033","title":"Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635087033?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:18","pubTimestamp":1778851093,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Jasper Therapeutics (JSPR) to $3 from $4 and keeps a Sector Perform rating on the shares. The firm c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-3-from-4-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-3-from-4-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089816","title":"TD Cowen Downgrades Jasper Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089816","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089816?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:22","pubTimestamp":1778844123,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (JSPR) has an average rating of overweight and mean price target of $9.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TD","COWN","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088655","title":"Jasper Therapeutics Inc : TD Cowen Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088655?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:03","pubTimestamp":1778839396,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nFWN41S0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635006317","title":"Jasper Therapeutics downgraded to Hold from Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2635006317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635006317?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:40","pubTimestamp":1778838009,"startTime":"0","endTime":"0","summary":"TD Cowen downgraded Jasper Therapeutics (JSPR) to Hold from Buy without a price target The company is “now at a critical juncture,” the analyst tel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-downgraded-to-hold-from-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-downgraded-to-hold-from-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR","TD","COWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721200","title":"Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721200","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721200?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:55","pubTimestamp":1778795752,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryJasper Therapeutics Inc JSPR.OQ reported a quarterly adjusted loss of 32 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635472377","title":"Jasper Therapeutics Q1 net loss narrows 94% to $1.17 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635472377","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635472377?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:12","pubTimestamp":1778789551,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics posted a net loss of USD 1.17 million for the quarter ended March 31, 2026, narrowing 94% from the year-ago period.Operating loss narrowed 50% to USD 10.95 million, while total operating expenses fell 50% to USD 10.95 million.Research and development expense dropped 64% to USD 5.81 million, while general and administrative costs eased 9% to USD 5.14 million.Total other income climbed to USD 9.78 million from USD 561,000, driven by a USD 9.64 million gain from change in fair value of warrant liability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbhFhDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728021","title":"Jasper Therapeutics Q1 Net Income USD -1.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728021?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX5E5923:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635233667","title":"Jasper Therapeutics Q1 EPS USD -0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2635233667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635233667?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX5E5923:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635998725","title":"Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635998725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635998725?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., May  14, 2026  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295352/0/en/Jasper-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633541894","title":"Jasper Therapeutics Inc  expected to post a loss of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633541894","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633541894?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:37","pubTimestamp":1778247425,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc  expected to post a loss of49cents a share - Earnings Preview Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to  show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1HW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543387","title":"Jasper Therapeutics Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624543387?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:16","pubTimestamp":1775063760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 13:16 ET (17:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513313","title":"Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513313","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513313?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:59","pubTimestamp":1775044780,"startTime":"0","endTime":"0","summary":"Evercore ISI lowered the firm’s price target on Jasper Therapeutics (JSPR) to $7 from $12 and keeps an Outperform rating on the shares. The firm ad...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-7-from-12-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-7-from-12-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623216833","title":"Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623216833","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623216833?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:53","pubTimestamp":1774904023,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51553686/jasper-therapeutics-q4-eps-0-32-beats-0-64-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623218943","title":"Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623218943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623218943?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:37","pubTimestamp":1774903033,"startTime":"0","endTime":"0","summary":"“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-reports-q4-eps-32c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-reports-q4-eps-32c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329427","title":"Jasper Therapeutics Q4 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329427?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:32","pubTimestamp":1774902731,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLXE0F294:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623932949","title":"Jasper Therapeutics FY25 net loss narrows to $75.8 million; cash drops to $28.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623932949","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623932949?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:30","pubTimestamp":1774902656,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics posted Q4 net loss of USD 9.1 million, narrowing from a year earlier, while full-year net loss widened to USD 75.8 million.Operating loss totaled USD 15.8 million for the quarter, improving from the prior-year period.Cash and cash equivalents fell to USD 28.7 million at Dec. 31, 2025.Briquilimab showed updated CSU data with 67% complete response at 12 weeks in BEACON Cohort 9.1, while 75% achieved complete response or well-controlled disease at 12 weeks in the open-label extension.Management said it remains on track to start enrolling patients in a Phase 2b/3 CSU study in the second half of 2026, pending capital availability.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1ry4Bg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4588","JSPR","BK4139","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4112","IE00B64PRP62.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623532944","title":"Press Release: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623532944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623532944?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:30","pubTimestamp":1774902600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March 30, 2026  -- Jasper Therapeutics, Inc.  , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit  to address mast cell driven diseases such as chronic spontaneous urticaria , chronic inducible urticaria  and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update.\"Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,\" said Jeet Mahal, President and Chief Executive Officer of Jasper. \"We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients. We are finalizing dose selection for the Phase 2b portion of our planned Phase 2b/3 study in CSU where we will evaluate two ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707892","title":"Jasper Therapeutics Inc : UBS Assumes Coverage With Neutral Rating; Target Price $1.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707892?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:07","pubTimestamp":1774278465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770248","title":"UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770248","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770248?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:58","pubTimestamp":1774277906,"startTime":"0","endTime":"0","summary":"Price: 1.18, Change: -0.05, Percent Change: -4.47","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jaspertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0823},{"period":"1month","weight":-0.1904},{"period":"3month","weight":-0.2543},{"period":"6month","weight":-0.494},{"period":"1year","weight":-0.8254},{"period":"ytd","weight":-0.5355}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.285776},{"month":2,"riseRate":0.428571,"avgChangeRate":0.093912},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.063229},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.031704},{"month":5,"riseRate":0.714286,"avgChangeRate":0.028386},{"month":6,"riseRate":0.5,"avgChangeRate":-0.094073},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.099771},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007485},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.2127},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.027786},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.069737},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.008174}],"exchange":"NASDAQ","name":"Jasper Therapeutics","nameEN":"Jasper Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jasper Therapeutics,JSPR,Jasper Therapeutics股票,Jasper Therapeutics股票老虎,Jasper Therapeutics股票老虎国际,Jasper Therapeutics行情,Jasper Therapeutics股票行情,Jasper Therapeutics股价,Jasper Therapeutics股市,Jasper Therapeutics股票价格,Jasper Therapeutics股票交易,Jasper Therapeutics股票购买,Jasper Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}